FDA patient-focused narcolepsy meeting will be held Sept. 24

In April the Food and Drug Administration announced that narcolepsy was selected as one of the disease areas to be addressed during the first three years of its Patient-Focused Drug Development initiative. Last week the FDA announced that it will hold a public meeting to gather patient and patient stakeholder input on how narcolepsy impacts daily life and on current approaches to treating narcolepsy. The public meeting will be held Tuesday, Sept. 24, 2013, from 1 p.m. to 5 p.m. at the FDA White Oak Campus in Silver Spring, Md.  Registration is free and will be on a first-come, first-served basis. Seating will be limited, so early registration is recommended. Those who are unable to attend the meeting in person can register to view a live webcast of the meeting. Registration to attend the meeting must be received by Sept. 13, 2013. Electronic or written comments must be submitted by Nov. 25, 2013. Complete details about the FDA narcolepsy meeting are available in the notice that was published in the Federal Register on July 19.

2013-07-25T00:00:00+00:00 July 25th, 2013|Research|